Liraglutide in Type 1 Diabetes

NCT01722240 on ClinicalTrials.gov · last registry update 2024-01-23

A small phase 3 — 69 participants, against a typical 424. The sponsor logged completion for 1 January 2019. Primary outcome, as filed: HbA1c (%). liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University at Buffalo
Sponsor type: Other
Enrollment: 69
Started: 2012-11-01
Primary completion: 2019-01-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c (%)

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.